Rehovot News (Center, Israel)

Foamix’s first-in-class Minocycline Foam - now in phase II. Most Dermatologists are concerned with Oral Minocycline side effects and will prefer prescribing their patients Topical Minocycline for Rosacea, Acne, Skin Infections and Wounds.

BiondVax Announces Receipt of Ethics (“Helsinki”) Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine

BiondVax receives funding based on their work on a Universal Flu Vaccine, receiving an additional $1 Million of funding from the Israel Chief Scientist’s office and signing of the final agreement with Yorkville Advisors for $7m

BiondVax Reports Positive Interim Safety Results from Second Phase I/II Universal Influenza Vaccine Trial BiondVax’s Multimeric-001 Universal Flu Vaccine Shown to be Safe and Well Tolerated in trial of 60 elderly participants

BiondVax Pharmaceuticals Ltd. (TASE: BNDK), an Israeli biopharmaceutical company and developer of a Universal Influenza Vaccine, today announced that it has signed a term sheet for a 3 year $7 million standby equity distribution agreement

Atom Limited Releases Coach Assistant 1.0.1 - refined version of eLearning coaching tool

Coach Assistant announced that York University chooses Coach Assistant Online Tool solution to serve as their student's internal learning and communication system.

Instructions to make solar power and wind power at home.